The group’s principle activity is to develop treatments for gastrointestinal and genitourinary disorders. The group’s products include DDP733 for the treatment of irritable bowel syndrome with constipation, DDP733 for the treatment of nocturnal gastroesophageal reflux disease, and P225 for the treatment of irritable bowel syndrome with diarrhea. The group operates from United States.
